Tumor Regression and Autoimmunity after Reversal of a Functionally Tolerant State of Self-reactive CD8+ T Cells

Many tumor-associated antigens are derived from nonmutated “self” proteins. T cells infiltrating tumor deposits recognize self-antigens presented by tumor cells and can be expanded in vivo with vaccination. These T cells exist in a functionally tolerant state, as they rarely result in tumor eradication. We found that tumor growth and lethality were unchanged in mice even after adoptive transfer of large numbers of T cells specific for an MHC class I–restricted epitope of the self/tumor antigen gp100. We sought to develop new strategies that would reverse the functionally tolerant state of self/tumor antigen-reactive T cells and enable the destruction of large (with products of perpendicular diameters of >50 mm2), subcutaneous, unmanipulated, poorly immunogenic B16 tumors that were established for up to 14 d before the start of treatment. We have defined three elements that are all strictly necessary to induce tumor regression in this model: (a) adoptive transfer of tumor-specific T cells; (b) T cell stimulation through antigen-specific vaccination with an altered peptide ligand, rather than the native self-peptide; and (c) coadministration of a T cell growth and activation factor. Cells, vaccination, or cyto-kine given alone or any two in combination were insufficient to induce tumor destruction. Autoimmune vitiligo was observed in mice cured of their disease. These findings illustrate that adoptive transfer of T cells and IL-2 can augment the function of a cancer vaccine. Furthermore, these data represent the first demonstration of complete cures of large, established, poorly immunogenic, unmanipulated solid tumors using T cells specific for a true self/tumor antigen and form the basis for a new approach to the treatment of patients with cancer.

[1]  Jonathan J. Lewis,et al.  A Single Heteroclitic Epitope Determines Cancer Immunity After Xenogeneic DNA Immunization Against a Tumor Differentiation Antigen1 , 2003, The Journal of Immunology.

[2]  E. Wherry,et al.  Therapeutic use of IL-2 to enhance antiviral T-cell responses in vivo , 2003, Nature Medicine.

[3]  E. Wherry,et al.  Viral Persistence Alters CD8 T-Cell Immunodominance and Tissue Distribution and Results in Distinct Stages of Functional Impairment , 2003, Journal of Virology.

[4]  A. Sette,et al.  Normal Tissue Depresses While Tumor Tissue Enhances Human T Cell Responses In Vivo to a Novel Self/Tumor Melanoma Antigen, OA1 , 2003, The Journal of Immunology.

[5]  L. Chin,et al.  Components of the Rb pathway are critical targets of UV mutagenesis in a murine melanoma model , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[6]  M. Nishimura,et al.  Increasing tumor antigen expression overcomes "ignorance" to solid tumors via crosspresentation by bone marrow-derived stromal cells. , 2002, Immunity.

[7]  S. H. van der Burg,et al.  Effective therapeutic anticancer vaccines based on precision guiding of cytolytic T lymphocytes , 2002, Immunological reviews.

[8]  M. Raffeld,et al.  Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes , 2002, Science.

[9]  S. Rosenberg,et al.  Expression of a "self-"antigen by human tumor cells enhances tumor antigen-specific CD4(+) T-cell function. , 2002, Cancer research.

[10]  M. Perales,et al.  Redundant and alternative roles for activating Fc receptors and complement in an antibody-dependent model of autoimmune vitiligo. , 2002, Immunity.

[11]  Drew M. Pardoll,et al.  Vaccines: Spinning molecular immunology into successful immunotherapy , 2002, Nature Reviews Immunology.

[12]  D. Speiser,et al.  Tumor Growth Enhances Cross-Presentation Leading to Limited T Cell Activation without Tolerance , 2002, The Journal of experimental medicine.

[13]  P. Shrikant,et al.  Activation-Induced Nonresponsiveness: A Th-Dependent Regulatory Checkpoint in the CTL Response1 , 2002, The Journal of Immunology.

[14]  J. Drazba,et al.  Augmentation Versus Inhibition: Effects of Conjunctional OX-40 Receptor Monoclonal Antibody and IL-2 Treatment on Adoptive Immunotherapy of Advanced Tumor1 , 2001, The Journal of Immunology.

[15]  P. Duray,et al.  Neonatal sunburn and melanoma in mice , 2001, Nature.

[16]  Rolf M. Zinkernagel,et al.  Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction , 2001, Nature.

[17]  Steven A. Rosenberg,et al.  Progress in human tumour immunology and immunotherapy , 2001, Nature.

[18]  A. Houghton,et al.  Immunity against cancer: lessons learned from melanoma. , 2001, Current opinion in immunology.

[19]  B. Seliger,et al.  Characterization of the Major Histocompatibility Complex Class I Deficiencies in B 16 Melanoma Cells 1 , 2001 .

[20]  E. Jaffee,et al.  Enhanced antigen-specific antitumor immunity with altered peptide ligands that stabilize the MHC-peptide-TCR complex. , 2000, Immunity.

[21]  R. Schreiber,et al.  Eradication of established tumors by CD8+ T cell adoptive immunotherapy. , 2000, Immunity.

[22]  V. Engelhard,et al.  Self-Tolerance to the Murine Homologue of a Tyrosinase-Derived Melanoma Antigen , 2000, The Journal of experimental medicine.

[23]  N. Restifo,et al.  The future of interleukin-2: enhancing therapeutic anticancer vaccines. , 2000, The cancer journal from Scientific American.

[24]  S. Rosenberg,et al.  Recognition of shared melanoma antigens in association with major HLA-A alleles by tumor infiltrating T lymphocytes from 123 patients with melanoma. , 2000, Journal of immunotherapy.

[25]  N. Restifo,et al.  Autoimmunity and the immunotherapy of cancer: targeting the "self" to destroy the "other". , 2000, Critical reviews in immunology.

[26]  Jonathan J. Lewis,et al.  Coupling and Uncoupling of Tumor Immunity and Autoimmunity , 1999, The Journal of experimental medicine.

[27]  H. Bien,et al.  Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40 , 1999, Nature Medicine.

[28]  R. Offringa,et al.  Recombinant virus vaccination against "self" antigens using anchor-fixed immunogens. , 1999, Cancer research.

[29]  Mario Roederer,et al.  Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients , 1999, Nature Medicine.

[30]  B. Moss,et al.  Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[31]  Yang Liu,et al.  Cytotoxic T Lymphocytes to An Unmutated Tumor Rejection Antigen P1A: Normal Development but Restrained Effector Function In Vivo , 1999, The Journal of experimental medicine.

[32]  P. Coulie,et al.  Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE‐3 and presented by HLA‐A1 , 1999, International journal of cancer.

[33]  Jonathan J. Lewis,et al.  Heteroclitic Immunization Induces Tumor Immunity , 1998, The Journal of experimental medicine.

[34]  J. Wolchok,et al.  Tumor immunity and autoimmunity induced by immunization with homologous DNA. , 1998, The Journal of clinical investigation.

[35]  D. Jong,et al.  Localization in situ of costimulatory molecules and cytokines in B‐cell non‐Hodgkin’s lymphoma , 1998, Immunology.

[36]  B. Moss,et al.  gp100/pmel 17 Is a Murine Tumor Rejection Antigen: Induction of “Self”-reactive, Tumoricidal T Cells Using High-affinity, Altered Peptide Ligand , 1998, The Journal of experimental medicine.

[37]  F. Marincola,et al.  Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma , 1998, Nature Medicine.

[38]  A. Abbas,et al.  Homeostasis and self-tolerance in the immune system: turning lymphocytes off. , 1998, Science.

[39]  Dirk Schadendorf,et al.  Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells , 1998, Nature Medicine.

[40]  D. Pardoll,et al.  Induction of antigen-specific T cell anergy: An early event in the course of tumor progression. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[41]  P. Srivastava,et al.  Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations. , 1997, Science.

[42]  D. Hanahan,et al.  Self Antigens Expressed by Solid Tumors Do Not Efficiently Stimulate Naive or Activated T Cells: Implications for Immunotherapy , 1997, The Journal of experimental medicine.

[43]  J. Bluestone,et al.  Antigenic Cancer Cells Grow Progressively in Immune Hosts without Evidence for T Cell Exhaustion or Systemic Anergy , 1997, The Journal of experimental medicine.

[44]  N. Restifo,et al.  Identification of a Kb-restricted CTL epitope of beta-galactosidase: potential use in development of immunization protocols for "self" antigens. , 1997, Methods.

[45]  S. Rosenberg,et al.  Cloning and characterization of the genes encoding the murine homologues of the human melanoma antigens MART1 and gp100. , 1997, Journal of immunotherapy.

[46]  K. Haas The Red Star goes to war. , 1997, Veterinary heritage : bulletin of the American Veterinary History Society.

[47]  S. Rosenberg,et al.  Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy. , 1996, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

[48]  S. Rosenberg,et al.  IL-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases. , 1995, Journal of immunology.

[49]  S. Rosenberg,et al.  Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen. , 1995, Journal of immunology.

[50]  V. Kouskoff,et al.  Cassette vectors directing expression of T cell receptor genes in transgenic mice. , 1995, Journal of immunological methods.

[51]  E. Jaffee,et al.  Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. , 1993, Proceedings of the National Academy of Sciences of the United States of America.